Sorrento Announces Phase 3 Trial Met Primary Endpoint and Key Secondary Endpoint in Mild or Moderate COVID-19 Adult Patients Treated with Ovydso (Olgotrelvir), an Oral Mpro Inhibitor as a Standalone Treatment for COVID-19
In the phase 3 trial, a randomized double blind and placebo-controlled pivotal study, 1,212 mild or moderate COVID-19 patients were enrolled and treated with OVYDSO™ (Olgotrelvir) or placebo.
Abivertinib Shows Promise Treating Marginal Zone Lymphoma
Abivertinib (Fujovee; Sorrento Therapeutics), an irreversible Bruton tyrosine kinase (BTK) inhibitor, produced promising results in patients with relapsed/refractory marginal zone lymphoma (MZL) in a recent phase 2a trial (NCT03060850).
Abivertinib Produces Responses in Relapsed/Refractory Marginal Zone Lymphoma
Treatment with the irreversible BTK inhibitor abivertinib (Fujovee) led to responses and disease control in patients with relapsed/refractory marginal zone lymphoma (MZL), according to data from a phase 2a trial (NCT03060850) conducted in China.
Sorrento Therapeutics Announces the FDA IND Clearance of STI-1558, An Oral M(pro) and Cathepsin L Inhibitor to Treat COVID-19
Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today announced the FDA clearance of a Phase 1 study of its oral main viral protease (Mpro) inhibitor, STI-1558, in patients with impaired renal and hepatic function
ACEA Biosciences Presents Efficacy and Safety Data From AC0010 Phase I/II Clinical Trial for Treatment of Advanced Non-Small Cell Lung Cancer at the WCLC 2016 Conference
Novel EGFR tyrosine kinase inhibitor AC0010 displays high efficacy, tolerability, and safety in phase I/II clinical trials. ACEA Biosciences, Inc. presented today updated efficacy and… Read more »
ACEA Biosciences Announces Data Presentation at WCLC 2016 Conference: New AC0010 Data to Be Presented
Clinical trial results for novel EGFR inhibitor AC0010 will be presented December 7th at World Conference on Lung Cancer. ACEA Biosciences, Inc. announced today that… Read more »
ACEA Biosciences Appoints Li Xu, M.D. as Chief Medical Officer
Former Vice President and Head of the Oncology Business Unit at Jiangsu Hengrui Medicine assumes position as Chief Medical Officer at ACEA Biosciences. ACEA Biosciences… Read more »
ACEA Biosciences Announces the Successful Completion of 30 Million USD in Venture Funding
ACEA Biosciences looks to its future with investments from Lilly Asia Ventures and Qiming Venture Partners. ACEA Biosciences, Inc., a privately held drug discovery and… Read more »